Wellness brand Maxine+Morgan is launching a clinical study to investigate the effectiveness of its custom herbal blend of CBD, turmeric, ginger and other natural ingredients for menstrual symptom relief.
In a three-month long, blind placebo-controlled study, participants will record their pain levels and quality of life twice a day.
At random, the 70 participants will receive a Maxine+Morgan herbal supplement, Ibuprofen, and placebo in order to compare results.
"With the clinical study, we're hoping to continue the conversation around women's wellness and ways in which we can use the amazing healing qualities of naturally derived herbs to influence an uninterrupted lifestyle,” Ariel Morgan, CEO and president of Maxine+Morgan, told Benzinga. “It's important to us that we leverage our resources and invest in research, analysis and experiential data to efficiently support our consumers needs.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.